logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Cassava Sciences, Moderna and Sorrento Therapeutics All Have News

News from Cassava Sciences, Moderna and Sorrento Therapeutics  Cassava Sciences  Cassava Sciences ( SAVA ) announced that clinical results of its Phase 2b study of sumifilam have been selected as a late-breaking oral presentation by the 13th international conference on...

Read More

September 30, 2020

0

RegenxBio is Rebounding. See Also: A Scientifically Valuable Agreement Between CRISPR Therapeutics and KSQ Therapeutics

RegenxBio Rebounding RegenxBio ( RGNX ) has the viral vectors which could safely deliver genes into the cells. The firm has improved the adeno-associated viruses making them safe and effective gene delivery vehicles. One of the three currently approved gene...

Read More

October 15, 2019

0

The FDA Lifted the Clinical Hold on Solid Biosciences' IGNITE DMD Phase 1/2 Trial Sending the Stock Price Over 131%

Solid Biosciences Clinical Hold on IGNITE DMD is Lifted by the FDA Solid Biosciences ( SLDB ) - a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that the U.S. FDA has lifted the clinical...

Read More

October 1, 2020

0

CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab's Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma

CASI Pharmaceuticals Partner, BioInvent International, Announced Positive Interim Results for NHL CASI Pharmaceuticals ( CASI ) partner BioInvent International ( BINV ) announced positive interim results from the Phase I/IIa trial of the novel anti-FcγRIIB product BI-1206 when combined with...

Read More

January 28, 2021

0

Bayer Decision to Advance IONIS-FXI-LRx Following Positive Results. See Also: Why Hepion Pharmaceuticals Stock Almost Doubled Today

Bayer Decision to Advance IONIS-FXI-LRx for Clotting Disorders On October 9, 2019 Ionis Pharmaceuticals ( IONS ) announced it had been notified by its partner Bayer ( BAYN ) about the decision to advance IONIS-FXI-LRx  following positive clinical results. IONIS-FXI-LRx ...

Read More

October 17, 2019

0

Compugen Adds an Immuno-Oncology Pioneer to its Scientific Advisory Board. See Also: The New War Against Aging

Compugen New Addition, Dr. Nils Lonberg, PhD. Compugen ( CGEN ) announced the addition of Nils Lonberg, Ph.D., to its Scientific Advisory Board (SAB). Dr. Lonberg is a pioneer in the field of immuno-oncology and has more than 30 years...

Read More

October 8, 2020

0

Why Seattle Genetics Gained $13.29; Currently Trading at $100.69; Meeting the Prohost 2019 Target

Seattle Genetics Announced Positive Results for HER2CLIMB Trial Seattle Genetics ( SGEN ) announced positive topline results from the HER2CLIMB trial evaluating tucatinib in HER2- positive breast cancer .  The trial compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab...

Read More

October 21, 2019

0

Cassava Sciences Product, Simufilam, Improved the Cognition and Behavior of Alzheimer's Patients Following Six Months of Treatment

Cassava Sciences Announced Simufilam Results for Alzheimer's Cassava Sciences ( SAVA ) announced impressive results of an interim analysis from an open-label study of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam improved both patients’ cognition and...

Read More

February 2, 2021

0

Roche and Spark Therapeutics: Gene Therapy SPK-8016 Demonstrating Promising Results on Adults with Severe Hemophilia A

Roche Group and Spark Therapeutics Gene Therapy Showing Promising Results Looking for gene therapy treatments for chronic debilitating life-threatening diseases we fell on news from Spark Therapeutics, a member of the Roche Group ( RHHBY ) ;   the firm...

Read More

February 5, 2021

0

Celldex Therapeutics Doses the First Patient with its CDX-0159 Product for Chronic Spontaneous Urticaria

Celldex Therapeutics After an expected resurrection, Celldex Therapeutics ( CLDX ) stock recovered and went as high as over $19 from less than $2 after an exaggerated selloff caused by  investors following the failure to treat the still untreatable glioblastoma...

Read More

October 13, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 104
  • 105
  • 106
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy